GMCSF-Interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer

Journal of Internal Medicine

Volumn 269, Issue 1, 2011, Pages 74-84

  Williams, P ^a   Galipeau, J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B regulatory cells; GMCSF; Interleukin; Interleukin receptor; Myeloid APCs; NK cells

Indexed keywords

CD8 ANTIGEN; GRANULOCYTE COLONY MACROPHAGE STIMULATING FACTOR INTERLEUKIN 15 FUSION PROTEIN; GRANULOCYTE COLONY MACROPHAGE STIMULATING FACTOR INTERLEUKIN 2 FUSION PROTEIN; GRANULOCYTE COLONY MACROPHAGE STIMULATING FACTOR INTERLEUKIN 21 FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SURFACE; CONFERENCE PAPER; DOWN REGULATION; EFFECTOR CELL; IMMUNE RESPONSE; INFLAMMATION; MELANOMA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 78650212294     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02314.x     Document Type: Conference Paper

References (79)

1. Mc Cormack O, Chung WY, Fitzpatrick P et al. Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer 2008; 98: 1141-6.
2. Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-53.
3. Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000; 164: 762-7.
4. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001; 70: 478-90.
5. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
6. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
7. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-6.
8. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
9. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-83.
10. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-4.
11. Schadendorf D, Algarra SM, Bastholt L et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009; 20(Suppl 6): vi41-50.
12. Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-77.
13. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37: 117-32.
14. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107: 2409-14.
15. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903.
16. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-8.
17. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-22.
18. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
19. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008; 105: 10113-8.
20. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
21. Asao H, Okuyama C, Kumaki S et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167: 1-5.
22. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity; 2010; 32: 79-90.
23. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10: 225-35.
24. Zorn E, Nelson EA, Mohseni M et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-9.
25. Laurence A, Tato CM, Davidson TS et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26: 371-81.
26. Neill DR, McKenzie AN. T(H)9: the latest addition to the expanding repertoire of IL-25 targets. Immunol Cell Biol 2010; 88: 502-4.
27. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002; 99: 3892-904.
28. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
29. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol 2002; 22: 51-6.
30. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-7.
31. Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 2009; 17: 380-8.
32. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007; 178: 732-9.
33. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008; 111: 229-35.
34. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson 3rd WE. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006; 177: 120-9.
35. Casey KA, Mescher MF. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol 2007; 178: 7640-8.
36. Kishida T, Asada H, Itokawa Y et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003; 8: 552-8.
37. Konforte D, Paige CJ. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 2006; 177: 8381-92.
38. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539-43.
39. Burgess AW, Metcalf D. Serum half-life and organ distribution of radiolabeled colony stimulating factor in mice. Exp Hematol 1977; 5: 456-64.
40. Sands H, Loveless SE. Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice. Int J Immunopharmacol 1989; 11: 411-6.
41. Stagg J, Wu JH, Bouganim N, Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 2004; 64: 8795-9.
42. Faisal M, Cumberland W, Champlin R, Fahey JL. Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood 1990; 76: 1580-5.
43. Penafuerte C, Bautista-Lopez N, Mohamed-Rachid B, Routy JP, Galipeau J. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res 2009; 69: 9020-8.
44. Zhang AL, Colmenero P, Purath U et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007; 110: 2484-93.
45. Liu C, Lou Y, Lizee G et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118: 1165-75.
46. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74.
47. Benham AM, Neefjes JJ. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. J Immunol 1997; 159: 5896-904.
48. Xu J, Ling EA. Upregulation and induction of major histocompatibility complex class I and II antigens on microglial cells in early postnatal rat brain following intraperitoneal injections of recombinant interferon-gamma. Neuroscience 1994; 60: 959-67.
49. Yang Y, Xiang Z, Ertl HC, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995; 92: 7257-61.
50. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329-36.
51. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49.
52. Cao S, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 1998; 58: 1695-9.
53. Munger W, DeJoy SQ, Jeyaseelan Sr R et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165: 289-93.
54. Pettit DK, Bonnert TP, Eisenman J et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem 1997; 272: 2312-8.
55. Rafei M, Wu JH, Annabi B, Lejeune L, Francois M, Galipeau J. A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood 2007; 109: 2234-42.
56. Rafei M, Hsieh J, Zehntner S et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009; 15: 1038-45.
57. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
58. Protheroe A. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer? Nat Clin Pract Oncol 2005; 2: 68-9.
59. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.
60. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87.
61. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-50.
62. Thompson JA, Curti BD, Redman BG et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26: 2034-9.
63. Williams P, Rafei M, Bouchentouf M et al. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 2010; 18: 1293-301.
64. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-26.
65. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-7.
66. Ferrero I, Held W, Wilson A, Tacchini-Cottier F, Radtke F, MacDonald HR. Mouse CD11c(+) B220(+) Gr1(+) plasmacytoid dendritic cells develop independently of the T-cell lineage. Blood 2002; 100: 2852-7.
67. Salio M, Cella M, Vermi W et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052-62.
68. Chauhan D, Singh AV, Brahmandam M et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009; 16: 309-23.
69. Vanbervliet B, Bendriss-Vermare N, Massacrier C et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003; 198: 823-30.
70. Pan J, Mestas J, Burdick MD et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5: 56.
71. Bartolome RA, Galvez BG, Longo N et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534-43.
72. de Totero D, Meazza R, Capaia M et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 2008; 111: 517-24.
73. Croker BA, Krebs DL, Zhang JG et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003; 4: 540-5.
74. Qin H, Wang L, Feng T et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 2009; 183: 97-105.
75. Duprez V, Ferrer M, Cornet V, Olive D, Dautry-Varsat A. Modulation of interleukin 2 internalization and interleukin 2-dependent cell growth by antireceptor antibodies. J Biol Chem 1991; 266: 1497-501.
76. Kyriakides TR, Foster MJ, Keeney GE et al. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol 2004; 165: 2157-66.
77. Beignon AS, Skoberne M, Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 2003; 4: 939-41.
78. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80.
79. Boasberg PD, Hoon DS, Piro LD et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-63.